Table 2.
Changes of various parameters between baseline and 3 months later.
| Parameters | Teneligliptin continued group | Canagliflozin add-on group | p |
|---|---|---|---|
| ΔBody weight (kg) | +0.7 ± 1.5 | −1.3 ± 1.9 | <0.0001 |
| ΔBMI (kg/m2) | +0.2 ± 0.6 | -0.9 ± 0.7 | <0.0001 |
| ΔFPG (mg/dL) | −4.3 ± 22.1 | −27.3 ± 40.3 | 0.0003 |
| ΔHbA1c (%) | −0.02 ± 0.4 | −0.7 ± 0.8 | <0.0001 |
| ΔSystolic BP (mmHg) | −0.4 ± 12.2 | −4.6 ± 10.5 | n.s. |
| ΔDiastolic BP (mmHg) | −0.2 ± 9.7 | −2.6 ± 9.4 | n.s. |
| ΔAST (U/L) | −1.8 ± 6.3 | −2.1 ± 9.1 | n.s. |
| ΔALT (U/L) | −1.3 ± 6.4 | −1.5 ± 11.6 | n.s. |
| ΔγGTP (U/L) | −0.9 ± 9.8 | −7.5 ± 22.5 | 0.03 |
| ΔCre (mg/dL) | −0.02 ± 0.07 | +0.02 ± 0.07 | 0.01 |
| ΔBUN (mg/dL) | −0.7 ± 3.9 | +2.3 ± 3.3 | 0.001 |
| ΔeGFR (mL/min/1.73 m2) | +3.2 ± 8.6 | −1.5 ± 8.8 | 0.04 |
| ΔTriglyceride (mg/dL) | −8.0 ± 40.7 | +6.2 ± 70.2 | n.s. |
| ΔHDL cholesterol (mg/dL) | −0.02 ± 4.8 | −2.1 ± 10.6 | n.s. |
| ΔLDL cholesterol (mg/dL) | −4.2 ± 13.6 | +0.1 ± 19.6 | n.s. |
| ΔUric acid (mg/dL) | −0.2 ± 0.6 | −0.6 ± 0.7 | 0.02 |